D-tace combined with MWA vs. c-tace combined with MWA in the treatment of advanced primary liver cancer: a prospective, observational study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100044104

Enrollment

Unknown

Registered

2021-03-11

Start date

2021-03-11

Completion date

Unknown

Last updated

2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary liver cancer

Interventions

DEB-TACE group:DEB-TACE and MWA

c-TACE group:c-TACE and MWA

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 years and = 90 g/L; b.ANC >= 1.5 x 10^9/L; c.PLT >= 80 x 10^9/L; (2) Biochemical tests should meet the following standards: a. ALB >= 29g/L; b. ALT and AST 45 ml /min (Cockcroft Gault formula); 9. The expected survival time is more than 3 months. The subjects voluntarily participated in this study and signed informed consent, with good compliance and follow-up.

Exclusion criteria

Exclusion criteria: 1. Extrahepatic metastasis of primary liver cancer, invasion of main portal vein and hepatic vein; 2. Abnormal coagulation function (INR > 1.5 or PT > ULN + 4 seconds or APTT > 1.5 ULN), with bleeding tendency or receiving thrombolysis or anticoagulation therapy; 3. History of hepatectomy, liver transplantation, interventional therapy and other malignant tumors; 4. Contraindications of TACE, pirarubicin and microwave ablation; 5. Carry out other clinical studies at the same time.

Design outcomes

Primary

Measure	Time frame
mPFS;	—

Secondary

Measure	Time frame
ORR, DCR;	—

Countries

China

Contacts

Public ContactYanhua Wang

Affiliated Hospital of Qingdao University

yhwelite@126.com+86 18661802668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026